Profile data is unavailable for this security.
About the company
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
- Revenue in INR (TTM)9.64bn
- Net income in INR2.75bn
- Incorporated1995
- Employees1.25k
- LocationIND Swift Laboratories LtdSCO 850NAC, Shivalik Enclave,, ManimajraCHANDIGARH 160101IndiaIND
- Phone+91 1 725061850
- Fax+91 1 722730504
- Websitehttps://www.indswiftlabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accent Microcell Ltd | 2.78bn | 346.64m | 8.16bn | 192.00 | 22.32 | 3.27 | 20.96 | 2.93 | 15.24 | 15.24 | 122.20 | 104.07 | 1.12 | 4.14 | 5.32 | 14,474,330.00 | 13.99 | -- | 15.95 | -- | 39.96 | -- | 12.47 | -- | 3.01 | 76.48 | 0.0046 | -- | 7.77 | -- | 9.60 | -- | -- | -- |
| Wanbury Ltd | 6.58bn | 646.86m | 8.73bn | 1.38k | 13.07 | -- | 11.04 | 1.33 | 19.13 | 19.13 | 194.16 | -- | -- | -- | -- | 4,758,967.00 | -- | 8.87 | -- | 101.40 | 55.07 | 41.82 | 9.84 | 5.62 | -- | 2.97 | -- | -- | 4.15 | 10.29 | -45.44 | -13.88 | 44.32 | -- |
| Venus Remedies Ltd | 7.00bn | 762.95m | 9.36bn | 1.30k | 12.27 | -- | 9.37 | 1.34 | 57.10 | 57.10 | 523.77 | -- | -- | -- | -- | 5,391,957.00 | -- | 6.67 | -- | 8.08 | 47.02 | 37.62 | 10.90 | 6.87 | -- | 1,849.19 | -- | -- | 7.72 | 13.81 | 59.05 | -- | 18.36 | -- |
| Bajaj Healthcare Ltd | 6.12bn | 523.16m | 10.03bn | 904.00 | 19.67 | -- | 12.58 | 1.64 | 16.15 | 15.36 | 188.83 | -- | -- | -- | -- | 6,774,850.00 | -- | 7.07 | -- | 13.07 | 46.31 | 37.17 | 8.54 | 8.22 | -- | 2.92 | -- | 5.83 | 14.61 | 5.76 | 399.64 | 11.21 | -12.65 | -- |
| Beta Drugs Ltd | -100.00bn | -100.00bn | 10.82bn | 399.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 15.08 | -- | 21.53 | -- | 40.30 | -- | 12.72 | -- | -- | -- | 0.00 | 22.54 | 31.89 | 28.96 | 37.92 | 19.23 | -- |
| Syncom Formulations (India) Ltd | 5.03bn | 689.58m | 11.34bn | 554.00 | 15.46 | -- | 15.26 | 2.26 | 0.78 | 0.78 | 5.58 | -- | -- | -- | -- | 9,072,854.00 | -- | 8.56 | -- | 11.58 | 40.05 | 34.81 | 13.72 | 10.15 | -- | 75.71 | -- | -- | 76.55 | 17.74 | 95.28 | 28.24 | 41.62 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.82bn | 409.03m | 11.39bn | 1.40k | 28.04 | -- | 22.63 | 4.04 | 6.07 | 6.07 | 41.76 | -- | -- | -- | -- | 2,012,738.00 | -- | 14.71 | -- | 17.26 | 63.66 | 60.59 | 14.53 | 12.54 | -- | 44.64 | -- | 39.88 | 28.76 | 11.13 | 146.45 | 47.72 | -28.44 | 65.72 |
| Sakar Healthcare Ltd | 2.31bn | 252.21m | 11.75bn | 342.00 | 46.11 | -- | 24.31 | 5.09 | 11.45 | 11.45 | 104.95 | -- | -- | -- | -- | 6,750,901.00 | -- | 4.73 | -- | 5.64 | 52.54 | 45.55 | 10.92 | 9.87 | -- | 3.66 | -- | -- | 15.80 | 16.44 | 49.96 | 12.71 | 19.34 | -- |
| IND Swift Laboratories Ltd | 9.64bn | 2.75bn | 11.90bn | 1.25k | 3.59 | -- | 3.70 | 1.23 | 38.28 | 38.28 | 122.91 | -- | -- | -- | -- | 7,738,014.00 | -- | 8.65 | -- | 10.59 | 51.55 | 40.96 | 28.56 | 14.35 | -- | -3.35 | -- | 0.00 | -56.15 | -6.35 | -40.50 | -- | 41.97 | -- |
| Lincoln Pharmaceuticals Ltd | 6.52bn | 878.34m | 12.48bn | 1.85k | 14.20 | -- | 12.25 | 1.91 | 43.86 | 43.86 | 325.55 | -- | -- | -- | -- | 3,518,272.00 | -- | 13.22 | -- | 15.46 | 53.64 | 50.82 | 13.47 | 14.56 | -- | 77.35 | -- | 3.32 | 7.35 | 10.03 | -11.74 | 9.87 | 20.13 | -- |
| Hester Biosciences Ltd | 3.14bn | 409.47m | 12.84bn | 562.00 | 40.05 | -- | 21.54 | 4.08 | 37.69 | 37.69 | 277.25 | -- | -- | -- | -- | 5,594,555.00 | -- | 5.39 | -- | 6.72 | 73.52 | 64.87 | 13.51 | 11.44 | -- | 9.65 | -- | 23.77 | 2.15 | 11.16 | 45.52 | -1.18 | -22.47 | 1.18 |
| Ngl Fine Chem Ltd | 4.47bn | 353.73m | 14.44bn | 456.00 | 40.81 | -- | 27.12 | 3.23 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
| Holder | Shares | % Held |
|---|---|---|
| Zeal Asset Management Ltd.as of 31 Dec 2025 | 4.01m | 4.92% |
